You are here

Lonza in joint venture to develop biotherapeutic products


SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6...

Market voices on: